002620.KS
Jeil Pharma Holdings Inc
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,780.00
−1.74%Year over year
Reported trailing growth
- Revenue
- -15.4%
- EBITDA
- —
- EBIT
- —
- EPS
- +124.1%
- Free cash flow
- +90.1%
- Operating cash flow
- +196.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -6.0%
- EBITDA
- +80.2%
- EBIT
- -15.1%
- Net income
- +128.6%
- EPS
- +128.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026